Skip to content

Veracyte VCYT Total costs & expenses

Total costs & expenses at other companies

Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Quest Diagnostics logo
Quest DiagnosticsDGX
Agilent Technologies logo
Agilent TechnologiesA
Abbott logo
AbbottABT

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's total costs & expenses?
Veracyte (VCYT) reported total costs & expenses of $78.51M in Q1 2026.
How has Veracyte's total costs & expenses changed year-over-year?
Veracyte's total costs & expenses increased by 2.5% year-over-year, from $76.6M to $78.51M.
What is the long-term trend for Veracyte's total costs & expenses?
Over 3 years (2021 to 2025), Veracyte's total costs & expenses has grown at a 0.4% compound annual growth rate (CAGR), from $301.42M to $304.76M.
What does total costs & expenses mean?
This represents the sum of all operating and non-operating costs incurred by the company to conduct its business activities during a specific period. It encompasses cost of revenue, research and development, selling, general and administrative expenses, and any impairment charges. This aggregate figure is essential for evaluating the company's overall cost management discipline and its ability to scale operations profitably.